中国医学创新
中國醫學創新
중국의학창신
MEDICAL INNOVATION OF CHINA
2014年
19期
31-33,34
,共4页
脑心综合征%依达拉奉%心肌酶%BNP%心肌损害
腦心綜閤徵%依達拉奉%心肌酶%BNP%心肌損害
뇌심종합정%의체랍봉%심기매%BNP%심기손해
Brain heart syndrome%Edaravone%Myocardial enzymes%BNP%Myocardial damage
目的：分析脑心综合征应用依达拉奉治疗前后心肌酶、BNP水平变化及意义。方法：选取2011年5月-2013年10月在本院进行治疗的脑心综合征患者80例为研究对象进行分析，按随机数字表法分为对照组和研究组，两组给予相同常规治疗，研究组在此基础上应用依达拉奉注射液治疗，对比两组患者治疗2周后临床总有效率、心肌酶（以血清AST、LDH、CK、CK-MB为主）和BNP变化。结果：研究组治疗总有效率82.5％，显著高于对照组57.5％，比较差异具有统计学意义（P<0.05）；研究组患者心肌酶指标（AST、LDH、CK、CK-MB）、BNP水平显著低于对照组，心肌损害和心力衰竭等情况比对照组稍轻，比较差异具有统计学意义（P<0.05）。结论：应用依达拉奉治疗脑心综合征患者心肌酶与BNP水平显著降低，可改善心肌损害与心力衰竭等症状，改善预后，有较高应用价值。
目的：分析腦心綜閤徵應用依達拉奉治療前後心肌酶、BNP水平變化及意義。方法：選取2011年5月-2013年10月在本院進行治療的腦心綜閤徵患者80例為研究對象進行分析，按隨機數字錶法分為對照組和研究組，兩組給予相同常規治療，研究組在此基礎上應用依達拉奉註射液治療，對比兩組患者治療2週後臨床總有效率、心肌酶（以血清AST、LDH、CK、CK-MB為主）和BNP變化。結果：研究組治療總有效率82.5％，顯著高于對照組57.5％，比較差異具有統計學意義（P<0.05）；研究組患者心肌酶指標（AST、LDH、CK、CK-MB）、BNP水平顯著低于對照組，心肌損害和心力衰竭等情況比對照組稍輕，比較差異具有統計學意義（P<0.05）。結論：應用依達拉奉治療腦心綜閤徵患者心肌酶與BNP水平顯著降低，可改善心肌損害與心力衰竭等癥狀，改善預後，有較高應用價值。
목적：분석뇌심종합정응용의체랍봉치료전후심기매、BNP수평변화급의의。방법：선취2011년5월-2013년10월재본원진행치료적뇌심종합정환자80례위연구대상진행분석，안수궤수자표법분위대조조화연구조，량조급여상동상규치료，연구조재차기출상응용의체랍봉주사액치료，대비량조환자치료2주후림상총유효솔、심기매（이혈청AST、LDH、CK、CK-MB위주）화BNP변화。결과：연구조치료총유효솔82.5％，현저고우대조조57.5％，비교차이구유통계학의의（P<0.05）；연구조환자심기매지표（AST、LDH、CK、CK-MB）、BNP수평현저저우대조조，심기손해화심력쇠갈등정황비대조조초경，비교차이구유통계학의의（P<0.05）。결론：응용의체랍봉치료뇌심종합정환자심기매여BNP수평현저강저，가개선심기손해여심력쇠갈등증상，개선예후，유교고응용개치。
Objective: To analyze brain heart syndrome before and after the treatment of comprehensive application of edaravone, myocardial enzyme levels and significance of BNP.Method: From 2011 May to 2013 October in our hospital for treatment of brain heart syndrome 80 patients were selected as the research object to analyze, who were randomly divided into control group and study group. The two groups were given the same routine treatment, and the study group based on the application of Edaravone injection treatment. The clinical total effective rate, myocardial enzymes (LDH, CK, serum AST, CK-MB and BNP change) between the two groups after two weeks of treatment were compared. Result: The treatment group total effective rate 82.5% was significantly higher than that of the control group 57.5%, with statistically significant differences (P<0.05). Patients with myocardial enzyme indexes (AST, LDH, CK, CK-MB), BNP levels were significantly lower than those of the control group, mean myocardial injury and heart failure were slightly lighter than those of the control group, with statistically significant differences (P<0.05).Conclusion: Application of edaravone in the treatment of cerebral cardiac syndrome in patients with myocardial enzyme and BNP level decreased significantly, can improve symptoms of heart failure, myocardial damage and improve prognosis, has higher application value.
